US FDA approves AstraZenca’s Tagrisso drug as first-line treatment for lung cancer

Tagrisso will now be the first treatment doctors use on lung cancer patients whose tumours have a specific mutation called an EFGR mutation

Lung cancer is the leading cause of cancer death among men and women

AstraZeneca PLC’s (LON:AZN) lung cancer drug, Tagrisso, has been approved by the US Food and Drug Administration as a first-line treatment.

The approval is for patients whose tumours have certain mutations have epidermal growth factor receptor (EGFR) mutations.

Tagrisso has been used as a second-line treatment in the US since last March, while the pill is still under regulatory review in the EU and Japan for use in the first-line treatment setting, with decisions expected later this year.

“Today's FDA approval of Tagrisso in the 1st-line setting is an exciting milestone for patients and our company,” Astra’s head of oncology Dave Fredrickson.

“Tagrisso delivered unprecedented median progression-free survival data across all pre-specified patient subgroups, including patients with or without CNS metastases, and could prolong the lives of more patients without their tumours growing or spreading.”

AstraZeneca shares edged 6p higher to £49.70 in early deals on Thursday.

Quick facts: AstraZeneca

Price: 7306 GBX

Market: LSE
Market Cap: £95.85 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Kromek Group 'well-positioned to report its highest ever full year revenues'

Kromek Group PLC's (LON:KMK) Dr Arnab Basu caught up with Proactive London's Andrew Scott to discuss their interims to October 2019. Revenues reached a record £5.3mln in the period - the rapid growth of the top line came as the County Durham-based firm got moving on the £100mln of...

10 hours, 8 minutes ago

2 min read